The goal of this observational study is to investigate the potential differences inthrombogenicity between black and white patients admitted with atherothrombotic eventsincluding acute coronary syndrome, multi-vessel coronary disease, and ischemic stroke.Participants will engage in laboratory testing and health outcome assessments.
Not Provided
Behavioral: Life and Medication Recommendations
Based on obtained subjective and objective data from patient-filled questionnaire and
laboratory testing respectively, lifestyle and medication recommendations will be
provided for secondary prevention of cardiovascular and cerebrovascular diseases
Inclusion Criteria:
- Patients ≥18 years of age admitted with ACS, AIS, or multi-vessel CAD
- Competent mental condition to provide informed consent and able to participate in
follow-ups
Exclusion Criteria:
- Pregnant women
- Currently enrolled in an investigational drug or device trial
- Undergoing treatment for neoplastic, autoimmune, or connective tissue disease
- COVID-19 infection within 30 days of enrollment
- Known history of hepatitis or HIV
- Deemed unfit to participate according to the investigator
- Known history of drug abuse
- Known platelet count of <100,000/mm3
- Hematocrit < 25%
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
Investigator: Paul Gurbel, MD
Contact: 410-591-2473
pgurbel@lifebridgehealth.org
Kevin Bliden, BS, MBA
4432441497
kbliden@lifebridgehealth.org
Jenna Brager, PhD, Study Chair
LifeBridge Health